NO20033429L - Fremgangsmåter for behandling av inflamatoriske og immunsykdommer ved anvendelse av inhibitorer av I-kappa-B kinase (IKK) - Google Patents

Fremgangsmåter for behandling av inflamatoriske og immunsykdommer ved anvendelse av inhibitorer av I-kappa-B kinase (IKK)

Info

Publication number
NO20033429L
NO20033429L NO20033429A NO20033429A NO20033429L NO 20033429 L NO20033429 L NO 20033429L NO 20033429 A NO20033429 A NO 20033429A NO 20033429 A NO20033429 A NO 20033429A NO 20033429 L NO20033429 L NO 20033429L
Authority
NO
Norway
Prior art keywords
ikk
kappa
kinase
inhibitors
methods
Prior art date
Application number
NO20033429A
Other languages
English (en)
Norwegian (no)
Other versions
NO20033429D0 (no
Inventor
James R Burke
Steven Nadler
Yuping Qiu
Robert M Townsend
Fred Christopher
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/965,977 external-priority patent/US6960585B2/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20033429D0 publication Critical patent/NO20033429D0/no
Publication of NO20033429L publication Critical patent/NO20033429L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20033429A 2001-02-01 2003-07-31 Fremgangsmåter for behandling av inflamatoriske og immunsykdommer ved anvendelse av inhibitorer av I-kappa-B kinase (IKK) NO20033429L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26585301P 2001-02-01 2001-02-01
US09/965,977 US6960585B2 (en) 2000-10-03 2001-09-27 Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
PCT/US2002/003060 WO2002060386A2 (en) 2001-02-01 2002-02-01 METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF IλB KINASE (IKK)

Publications (2)

Publication Number Publication Date
NO20033429D0 NO20033429D0 (no) 2003-07-31
NO20033429L true NO20033429L (no) 2003-09-24

Family

ID=26951465

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033429A NO20033429L (no) 2001-02-01 2003-07-31 Fremgangsmåter for behandling av inflamatoriske og immunsykdommer ved anvendelse av inhibitorer av I-kappa-B kinase (IKK)

Country Status (10)

Country Link
EP (1) EP1363993A4 (cs)
JP (1) JP2004529088A (cs)
AU (1) AU2002247059B2 (cs)
CA (1) CA2436770A1 (cs)
CZ (1) CZ20032287A3 (cs)
HU (1) HUP0304045A3 (cs)
MX (1) MXPA03006817A (cs)
NO (1) NO20033429L (cs)
PL (1) PL364111A1 (cs)
WO (1) WO2002060386A2 (cs)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960585B2 (en) * 2000-10-03 2005-11-01 Bristol-Myers Squibb Company Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
BR0114978A (pt) 2000-10-26 2004-04-20 Tularik Inc Composições e métodos que são úteis no tratamento de condições ou doenças inflamatórias, metabólicas, e proliferativas celulares
AR037641A1 (es) 2001-12-05 2004-11-17 Tularik Inc Moduladores de inflamacion
DE10237722A1 (de) 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
EP1556053A4 (en) 2002-10-31 2006-04-19 Amgen Inc ANTI-INFLAMMATORY AGENTS
TW200616967A (en) 2004-06-24 2006-06-01 Smithkline Beecham Corp Novel indazole carboxamides and their use
TW200626142A (en) 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
KR20080021077A (ko) 2005-06-30 2008-03-06 스미스클라인 비참 코포레이션 화합물
EP2266561A3 (en) * 2005-09-07 2011-05-18 Merck Serono S.A. IKK Inhibitors for the Treatment of Endometriosis
US20090175852A1 (en) 2006-06-06 2009-07-09 Schering Corporation Imidazopyrazines as protein kinase inhibitors
EP2489667B1 (en) * 2006-12-13 2015-04-15 ASKA Pharmaceutical Co., Ltd. Quinoxaline derivative
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
US9132087B2 (en) 2008-04-21 2015-09-15 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
WO2010000903A2 (es) * 2008-06-30 2010-01-07 Centro De Investigaciones Energéticas, Medioambientales Y Tecnológicas (Ciemat) Composición capaz de modular la actividad de ikkalpha para el tratamiento de enfermedades que cursan con acantolisis
RU2504544C2 (ru) 2008-10-02 2014-01-20 Асахи Касеи Фарма Корпорейшн 8-замещенные производные изохинолина и их применение
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
CN109689027A (zh) 2016-06-29 2019-04-26 奥德纳米有限公司 甘油三酯耳用制剂及其用途
EP3494994A1 (en) * 2017-12-07 2019-06-12 Universität zu Köln Combinations of ripk1- and ikk-inhibitors for the prevention or treatment of immune diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160097A (en) * 1977-01-07 1979-07-03 Westwind Pharmaceuticals, Inc. 1-(2-Phenylureylene)imidazoles
US5851812A (en) * 1997-07-01 1998-12-22 Tularik Inc. IKK-β proteins, nucleic acids and methods
US6235740B1 (en) * 1997-08-25 2001-05-22 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
US6030834A (en) * 1997-12-30 2000-02-29 Chiron Corporation Human IKK-beta DNA constructs and cells
GB0003154D0 (en) * 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
YU65502A (sh) * 2000-03-15 2005-11-28 Aventis Pharma Deutschland Gmbh. Supstituisani beta-karbolini sa ikb-kinaza inhibirajućim dejstvom
US6960585B2 (en) * 2000-10-03 2005-11-01 Bristol-Myers Squibb Company Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same

Also Published As

Publication number Publication date
NO20033429D0 (no) 2003-07-31
PL364111A1 (en) 2004-12-13
AU2002247059B2 (en) 2006-11-16
WO2002060386A3 (en) 2002-10-10
MXPA03006817A (es) 2003-11-13
HUP0304045A2 (hu) 2004-04-28
HUP0304045A3 (en) 2005-05-30
WO2002060386A2 (en) 2002-08-08
CZ20032287A3 (cs) 2004-02-18
EP1363993A2 (en) 2003-11-26
EP1363993A4 (en) 2008-11-12
CA2436770A1 (en) 2002-08-08
JP2004529088A (ja) 2004-09-24

Similar Documents

Publication Publication Date Title
NO20033429L (no) Fremgangsmåter for behandling av inflamatoriske og immunsykdommer ved anvendelse av inhibitorer av I-kappa-B kinase (IKK)
NO20025814D0 (no) Fremgangsmåte ved brönnfullföring
NO20035426D0 (no) Fremgangsmåte ved administrering av anti-TNF-D-antistoff
NO20031489D0 (no) Fremgangsmåte og anordning ved trekkbar broplugg
NO20003775D0 (no) FremgangsmÕte for behandling av inflammatoriske sykdommer ved anvendelse av varmesjokkproteiner
DK1352895T3 (da) Adamantanderivater til behandling af inflammatioriske immunologiske og kardiovaskulære sygdomme
NO20052760D0 (no) Fremgangsmate for behandling av kreft og beslektede fremgangsmater.
IS8451A (is) Aðferðir og hvarfefni til að meðhöndla ónæmisbólgusjúkdóma
NO20030265D0 (no) Fremgangsmåter ved behandling av borebrönner
NO20032229D0 (no) Fremgangsmåter for behandling av p38kinase-assosierte tilstander og pyrrolotriazin forbindelser nyttige som kinase inhibitorer
IS8410A (is) Aðferðir og hvarfefni til að meðhöndla ónæmisbólgusjúkdóma
DK1463683T3 (da) Fremgangsmåde og arrangement ved ladesøjle
NO20033854L (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
EP1539248A4 (en) INHIBITOR OF S100-p53 PROTEIN-PROTEIN INTERACTION AND METHOD OF SUPPRESSING CANCER USING THIS HEMMER
NO20014648D0 (no) Forbindelser og metoder for behandling av astma, allergi og inflammatoriske sykdommer
NO20033498D0 (no) Fremgangsmåte for behandling og törking av trevirke
NO20033506D0 (no) Parasittdrepende preparater og fremgangsmåter for anvendelse
IS8497A (is) Aðferðir og hvarfefni til að meðhöndla bólgusjúkdóma
NO20024867D0 (no) Fremgangsmåte og preparat for behandling av kreft ved administrering av apoptoseinduserende kjemoterapeutiske midler
NO334788B2 (no) Fremgangsmåte for behandling av søvnløshet
NO20023737D0 (no) Fremgangsmåte og preparater for behandling av en inflammatorisk lidelse
DK1381620T3 (da) Hypersulfaterede disaccharider og fremgangsmåder til anvendelse af samme til behandling af inflammationer
NO20033541D0 (no) Anvendelse av fosfodiesteraseinhibitorer av type 4 ved hjertemuskelsykdommer
NO20052264D0 (no) Pregahalinderivater for behandling av fibromyalgi og andre forstyrrelser
NO20034246D0 (no) Enkel dose av aromataseinhibitor for behandling av ufruktbarhet

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application